OssDsign Welcomes New Sales Vice President

OssDsign AB has hired Adam McCollister as sales vice president to lead U.S. sales strategy and execution, with a focus on accelerating the adoption of the company’s Catalyst nanosynthetic bone graft. He succeeds Eric Patermo, who was named vice president, Strategic Initiatives.

“I am excited to join OssDsign and help advance the commercial success of the Catalyst platform,” McCollister said. “Catalyst represents a differentiated, next-generation orthobiologic solution, and I look forward to working with the team to expand market penetration, strengthen customer engagement, and support continued growth in the U.S.”

McCollister is experienced in orthopedic sales and commercial leadership. Most recently, he was regional vice president at Treace Medical Concepts; before that, he worked in sales roles at Stryker Corp. and Tornier, and held leadership positions at Orthofix, where he supervised high-performing sales organizations and drove market expansion initiatives.

“We are pleased to welcome Adam to OssDsign at this important stage of our growth,” OssDsign CEO Mark Waugh said. “His deep industry expertise and proven ability to scale commercial teams and drive adoption of innovative technologies will be instrumental as we expand the U.S. footprint of Catalyst. We also thank Eric Patermo for his leadership and contributions as vice president, U.S. Sales. We are pleased that he will continue to support OssDsign in his new role as vice president, Strategic Initiatives, as we advance our mission to deliver value to shareholders and evidence-based solutions to surgeons and their patients.”

OssDsign is a developer and global provider of next-generation orthobiologics products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities. The company has a strong presence in the U.S. market. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.